Glycoprotein Ib-IX-V complex (GPIb-IX-V)

The glycoprotein Ib-IX-V complex (GPIb-IX-V) is a major platelet surface receptor and mechanoreceptor essential for primary hemostasis and thrombosis. As the second most abundant platelet surface receptor, it consists of four subunits (GPIbα, GPIbβ, GPIX, and GPV) organized in a highly integrated heteromeric structure that senses blood shear stress and mediates the first critical step in platelet adhesion to damaged blood vessel walls through binding to von Willebrand factor. The complex functions as a mechanoreceptor wherein pulling force on its ligand-binding domain unfolds an internal mechanosensory domain, triggering platelet activation, aggregation, and signaling cascades that initiate thrombus formation at sites of vascular injury. Dysfunction of GPIb-IX-V causes severe bleeding disorders such as Bernard-Soulier syndrome, while inappropriate activation contributes to thrombotic diseases including stroke and myocardial infarction. Additionally, antibody-mediated activation of GPIb-IX plays a role in immune thrombocytopenia, where platelet clearance is enhanced through desialylation. The complex binds numerous ligands beyond von Willebrand factor, including thrombin, P-selectin, and clotting factors, making it central to multiple vascular and platelet biology processes. As a potential therapeutic target, GPIb-IX-V offers opportunities for developing novel strategies to treat both bleeding and thrombotic disorders, though therapeutic development faces significant challenges in balancing the prevention of pathological thrombosis against maintenance of hemostatic function.

Other names

Platelet glycoprotein Ib-IX-V complexGP Ib complexGP Ib-V-IX

GPIb-IX activation occurs through a "trigger model" wherein pulling force exerted on GPIbα through its ligand-binding domain unfolds the mechanosensory domain, exposing trigger sequences that activate the receptor. Upon VWF binding and force application (from blood shear stress or antibody crosslinking), GPIb-IX activation leads to platelet desialylation through NEU1 activation, inside-out activation of integrin αIIbβ3, thromboxane A2 synthesis and release, degranulation, formation of platelet microparticles, and recruitment of signaling proteins like 14-3-3ζ. The binding affinity and epitope of ligands are less critical than the tensile force generated by bound ligands for receptor activation.